相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Andrew J. Armstrong et al.
EUROPEAN UROLOGY (2020)
Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
Seung Il Jung et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2020)
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2019)
Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong
Darren M. C. Poon et al.
CLINICAL GENITOURINARY CANCER (2018)
NCCN Asia Consensus Statement prostate cancer
Shiro Hinotsu et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer
Choung Soo Kim et al.
MEDICINE (2017)
Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries
Sung-Lang Chen et al.
SCIENTIFIC REPORTS (2017)
Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naive patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study
D. Ye et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer
Giuseppe Colloca et al.
CLINICAL GENITOURINARY CANCER (2016)
Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis
Raj Satkunasivam et al.
JOURNAL OF UROLOGY (2015)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
